NORGINE B.V. ENTERS INTO EXCLUSIVE LICENCE AND DISTRIBUTION AGREEMENTS FOR THE COMMERCIALISATION OF PLENVU® IN A NUMBER OF COUNTRIES IN LATIN AMERICA, SOUTHERN AFRICA, CENTRAL AND EASTERN EUROPE
12 February 2020
Norgine is committed to making information about its clinical research publicly available, irrespective of the outcomes, positive or negative, in order to support the scientific understanding of its medicines and medical devices and their benefits and risks to patients.
Norgine discloses clinical trial results of all new medicines and medical devices in accordance with the regulations to ensure rigorous assessment of their quality, safety and efficacy before they are approved and made available to patients. Regulatory review is maintained throughout the life cycle of our medicines and medical devices and the benefits and risks associated with these medicines and medical devices are continuously reviewed by Norgine in collaboration with regulatory authorities.
The results of our clinical trials in all stages of clinical development are disclosed in several ways: